TG Therapeutics TGTX Q2 2026: Revenue Surges but EPS Misses by 89%
As seen on the 24/7 Wall St. homepage on August 3, 2026.
BRIUMVI's commercial muscle delivered 70% revenue growth and pushed TG Therapeutics to raise full-year guidance to $950M, but a cash-incinerating R&D ramp to develop subcutaneous formulations crushed earnings per share to $0.05, missing consensus by 89%.
Continue ReadingShow less
BRIUMVI continued its remarkable commercial run in Q2 2026, with TG Therapeutics posting $240.3 million in revenue — a 70% increase year-over-year and about 5% above the analyst consensus of $229.8 million. The drug's momentum was strong enough that management raised its full-year revenue guidance to $950 million, a signal of sustained confidence in BRIUMVI's market penetration.
The earnings picture told a very different story. Reported EPS came in at just $0.05 against a consensus estimate of $0.44, a miss of roughly 89%. The culprit, per the company, was a sharp ramp-up in research and development spending tied to the development of subcutaneous formulations of BRIUMVI — an investment that consumed cash and overwhelmed the gains from top-line growth.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
The revenue trend over the past several quarters underscores just how fast this franchise has scaled, climbing from $73.5 million in Q2 2024 to $240.3 million in Q2 2026. Whether the R&D spending that pressured Q2 earnings translates into a next-generation product that extends BRIUMVI's competitive life is the central question investors will be watching in the quarters ahead.
Mentioned: TGTX